Eiger BioPharmaceuticals, Inc. reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Palo Alto, CA
SEC filing record 1 source field available
Fiscal year end
31 December
Eiger BioPharmaceuticals, Inc. has filed 694 SEC EDGAR filings since 05 Oct 2004

SEC filing history

Showing 176-200 of 687 matching filings.

Per page
25
Current page
8
4

FORM 4 SUBMISSION

Filing date
15 Mar 2021
Reporting date
12 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
15 Mar 2021
Reporting date
12 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
15 Mar 2021
Reporting date
12 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
15 Mar 2021
Reporting date
12 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
15 Mar 2021
Reporting date
12 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
15 Mar 2021
Reporting date
12 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
15 Mar 2021
Reporting date
12 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
15 Mar 2021
Reporting date
12 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
15 Mar 2021
Reporting date
12 Mar 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
S-8 File 333-254039

S-8

Filing date
09 Mar 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-87931

SC 13G/A filing

Filing date
16 Feb 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13D/A File 005-87931

AMENDMENT NO. 4 TO SCHEDULE 13D

Filing date
12 Feb 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-87931

EIGER BIOPHARMACEUTICALS, INC.

Filing date
11 Feb 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-87931

SC 13G/A filing

Filing date
29 Jan 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
4

FORM 4 SUBMISSION

Filing date
11 Jan 2021
Reporting date
08 Jan 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G File 005-87931

SC 13G

Filing date
11 Jan 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-87931

SC 13G/A filing

Filing date
04 Jan 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-251497

EFFECT filing

Filing date
31 Dec 2020
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
CORRESP

CORRESP filing

Filing date
28 Dec 2020
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
UPLOAD

UPLOAD filing

Filing date
23 Dec 2020
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
S-3 File 333-251497

S-3

Filing date
18 Dec 2020
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .